Genetic Aspects of Alzheimer Disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer disease (AD) is a genetically complex disorder. Mutations in 3 genes, presenilin 1, amyloid precursor protein, and presenilin 2, lead to early-onset familial AD in rare families with onset of disease occurring prior to age 65. Specific polymorphisms in apolipoprotein E are associated with the more common, late-onset AD occurring after age 65. In this review, we discuss current advances in AD genetics, the implications of the known AD genes, presenilin 1, presenilin 2, amyloid precursor protein, and apolipoprotein E, and other possible genes on the clinical diagnosis, treatment, and genetic counseling of patients and families with early- and late-onset AD. REVIEW SUMMARY: In addition to the mutations in 4 known genes associated with AD, mutations in other genes may be implicated in the pathogenesis of the disease. Most recently, 2 different research groups have reported genetic association between 2 genes, sortilin-related receptor and GAB2, and AD. These associations have not changed the diagnostic and medical management of AD. CONCLUSIONS: New research in the genetics of AD have implicated novel genes as having a role in the disease, but these findings have not been replicated nor have specific disease causing mutations been identified. To date, clinical genetic testing is limited to familial early-onset disease for symptomatic individuals and asymptomatic relatives and, although not recommended, amyloid precursor protein apolipoprotein E testing as an adjunct to diagnosis of symptomatic individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Future of Genetic Studies of Complex Human Diseases
Risch, N., & Merikangas, K. (1996) · Science · doi:10.1126/science.273.5281.1516 · Cited by 5,355
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“The 2 allele is associated with the lowest LOAD risk, whereas the 4 allele is associated with an increased risk for LOAD and a younger age of onset of dementia in a dose-dependent manner.(10,11) The increased risk for LOAD has also been demonstrated in different ethnic populations including African-Americans and Carib…”
BackgroundSystematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 2×
“org) that compiles up-to-date information on genetic association studies performed on AD and AD phenotypes, has organized and reviewed over 900 AD association studies and approximately 400 genes.(14) The AlzGene database organizes and ranks these findings in an attempt to sift through the hundreds of positive and nega…”
BackgroundRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 1×
“Despite these challenges, twin studies, which demonstrate a 60% concordance rate in monozygotic twins, and other investigations indicate that there may be several susceptibility genes along with APOE 4 that play a role in late-onset AD.(16,17)”
ResultThe neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167 · cited 2×
“Therefore, SORL1 may be a susceptibility factor rather than a deterministic gene.(28) Several groups have attempted to replicate these findings.”
BackgroundResultCampion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785 · cited 1×
“Mutations in APP, PSEN1, and PSEN2 may explain up to 71% of the familial EOAD cases, but other unknown EOAD genes may be identified.(36) As a susceptibility factor rather than causal gene, APOE testing is not currently recommended for asymptomatic individuals with a family history of late-onset disease except through…”
BackgroundHyperinsulinemia and risk of Alzheimer disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2004) · Neurology · doi:10.1212/01.wnl.0000140292.04932.87 · Cited by 683
The genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680 · cited 2×
“Recent publications have thoroughly explained the steps of mapping genes in common, complex disorders or specifically in AD.(19,32) In order for an association to be confirmed, the positive association must be replicated by independent studies and in different populations.”
BackgroundUtility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., Hyman, B. T., Crain, B., Tang, M.-X., & Phelps, C. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380804 · Cited by 547 · cited 1×
“Additionally, there is much debate about the clinical utility of APOE testing for diagnosis given APOE genotyping does not provide sufficient sensitivity or specificity to be used alone as a diagnostic test.(39) The presence of an 4 allele should not alter either the diagnostic evaluation or certainty.”
Background
Cited by
Prion-like mechanisms in neurodegenerative diseases
Frost, B., & Diamond, M. I. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2786 · Cited by 776
“In AD, the speed of cognitive decline, age of onset and the location and extent of Aβ plaque load vary considerabl”
BackgroundThe dysregulation of intracellular calcium in Alzheimer disease
Supnet, C., & Bezprozvanny, I. (2010) · Cell Calcium · doi:10.1016/j.ceca.2009.12.014 · Cited by 323
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237
Association between APOE ε4 Allele and Vascular Dementia: The Cache County Study
Chuang, Y.-F., Hayden, K. M., Norton, M. C., Tschanz, J., Breitner, J. C. S., Welsh-Bohmer, K. A., Zandi, P. P., & for the Cache County Investigators (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000285166 · Cited by 81
DNA-repair in mild cognitive impairment and Alzheimer's disease
Bucholtz, N., & Demuth, I. (2013) · DNA Repair · doi:10.1016/j.dnarep.2013.07.005 · Cited by 34
Metadata
- Authors
- Williamson, J., Goldman, J., & Marder, K. S.
- Venue
- The Neurologist
- Published
- 2009-03
- Volume
- 15
- Issue
- 2
- Pages
- 80-86
- ISSN
- 1074-7931 (ISSN-L)
- OpenAlex
- W2051408096
- Cited by
- 135
- References
- 13
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic Aspects of Alzheimer Disease. https://app.cochat.ai/papers/10.1097/nrl.0b013e318187e76b
- The paper
- Williamson, J., Goldman, J., & Marder, K. S. (2009). Genetic Aspects of Alzheimer Disease. The Neurologist. https://doi.org/10.1097/nrl.0b013e318187e76b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.